KRAS and non-small cell lung carcinoma: YAP also bypasses KRAS addiction in PDAC13, and functionally substitutes KRAS in murine lung cancer model14 and mediates drug resistance to drugs that target oncogenic RAS signalling in human non-small cell lung cancer cells19.